Diadema Partners’s Apogee Therapeutics APGE Stock Holding History

Diadema Partners’s Portfolio APGE Stock Details APGE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$18.7M	Buy	222,500 +11,400	+5%	+$828K	3.19%	6
2025 Q4	$15.9M	Buy	211,100 +83,700	+66%	+$5.27M	2.74%	8
2025 Q3	$5.06M	Sell	127,400 -28,900	-18%	-$1.1M	1.29%	28
2025 Q2	$6.79M	Buy	156,300 +30,000	+24%	+$1.14M	2.07%	16
2025 Q1	$4.72M	Buy	+126,300	New	+$4.88M	1.23%	21

Other funds holding APGE

T. Rowe Price Investment Management Baltimore, Maryland $145B AUM 22.78% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

VR Adviser New York $2.68B AUM 422.73% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

DCM

Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return

Diadema Partners's APGE Position: Q4 2025 in Review

Diadema Partners sold out of Apogee Therapeutics (APGE) in Q4 2025, closing a stake of 64,250 shares — an estimated $4.05M sold.

Diadema Partners first reported a position in APGE in Q4 2024 and held it in 4 quarters. The position peaked at $2.55M in Q3 2025. 206 funds tracked by Wall St. Rank hold APGE as of Q4 2025.

Diadema Partners reported no remaining Apogee Therapeutics position as of Q4 2025 after selling out during the quarter.
Diadema Partners sold 64,250 Apogee Therapeutics shares in Q4 2025, an estimated $4.05M.
Diadema Partners first reported a position in Apogee Therapeutics in Q4 2024 and held it in 4 quarters.
Diadema Partners's Apogee Therapeutics position peaked at $2.55M in Q3 2025.
206 funds tracked by Wall St. Rank held Apogee Therapeutics as of Q4 2025.

Based on Diadema Partners's 13F filing for Q4 2025, filed 17 Feb 2026.